ABBV vs. BIIB: AbbVie vs. Biogen Stock Comparison
This page compares AbbVie (ABBV) with Biogen (BIIB) using performance and risk, profitability, financial strength, growth, dividends, and valuation metrics.
Performance
Cumulative Growth
Trailing Returns
Performance at a Glance
| Metric | ABBV | BIIB |
|---|---|---|
| 1-Year Return | 22.21% | 51.20% |
Risk
Drawdown
Risk at a Glance
| Metric | ABBV | BIIB |
|---|---|---|
| 1-Year Volatility | 24.36% | 33.53% |
| Beta | 0.31 | 0.17 |
| 3-Month Avg. Volume | 6.43M | 1.16M |
Company Profile
AbbVie (ABBV) and Biogen (BIIB) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
| Profile Item | ABBV | BIIB |
|---|---|---|
| Name | AbbVie Inc. | Biogen Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 402.35 billion USD | 29.53 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | January 2, 2013 | September 17, 1991 |
| Security Type | Common Stock | Common Stock |
Valuation
Price-to-Earnings Ratio (TTM)
Biogen (BIIB) at 21.51 is near its industry’s usual P/E ratio, while AbbVie (ABBV) at 111.09 sits above its peer range — an unusually expensive price for ABBV’s trailing earnings.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
111.09
- ABBV
- 111.09
- Max
- 77.14
- Q3
- 43.78
- Median
- 24.68
- Q1
- 15.27
- Min
- 1.70
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
21.51
- Max
- 77.14
- Q3
- 43.78
- Median
- 24.68
- BIIB
- 21.51
- Q1
- 15.27
- Min
- 1.70
Price-to-Sales Ratio (TTM)
Biogen (BIIB) at 2.97 sits in the cheaper P/S ratio quartile while AbbVie (ABBV) at 6.40 prices around its industry’s middle — BIIB costs less per dollar of sales, though read it alongside growth and margins.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.40
- Max
- 55.38
- Q3
- 24.42
- Median
- 6.98
- ABBV
- 6.40
- Q1
- 3.30
- Min
- 0.01
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.97
- Max
- 55.38
- Q3
- 24.42
- Median
- 6.98
- Q1
- 3.30
- BIIB
- 2.97
- Min
- 0.01
Price-to-Book Ratio (MRQ)
AbbVie (ABBV) reports a negative P/B ratio of -60.45, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Biogen (BIIB) reports 1.58, ranking against industry peers normally.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
-60.45
- Max
- 13.23
- Q3
- 6.38
- Median
- 3.46
- Q1
- 1.64
- Min
- -5.17
- ABBV
- -60.45
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.58
- Max
- 13.23
- Q3
- 6.38
- Median
- 3.46
- Q1
- 1.64
- BIIB
- 1.58
- Min
- -5.17
Valuation at a Glance
| Metric | ABBV | BIIB |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 111.09 | 21.51 |
| Price-to-Sales Ratio (TTM) | 6.40 | 2.97 |
| Price-to-Book Ratio (MRQ) | -60.45 | 1.58 |
| Free Cash Flow Yield | 5.17% | 6.54% |
Profitability
Return on Equity (TTM)
Capital efficiency shows on one side only: Biogen (BIIB) earns 7.70% on shareholders’ equity, ranked against its industry; AbbVie (ABBV) has no ROE this period.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 101.32%
- Q3
- 2.92%
- Median
- -31.26%
- Q1
- -62.68%
- Min
- -158.89%
- ABBV
- --
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.70%
- Max
- 101.32%
- BIIB
- 7.70%
- Q3
- 2.92%
- Median
- -31.26%
- Q1
- -62.68%
- Min
- -158.89%
Net Profit Margin (TTM)
Biogen (BIIB) at 13.81% keeps the most of each sales dollar — above its industry’s net margin range — and AbbVie (ABBV) at 5.79% also retains a top-quartile share.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.79%
- Max
- 12.76%
- ABBV
- 5.79%
- Q3
- 4.00%
- Median
- 0.00%
- Q1
- -2.26%
- Min
- -11.53%
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.81%
- BIIB
- 13.81%
- Max
- 12.76%
- Q3
- 4.00%
- Median
- 0.00%
- Q1
- -2.26%
- Min
- -11.53%
Operating Profit Margin (TTM)
Both AbbVie (ABBV) at 32.16% and Biogen (BIIB) at 22.90% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
32.16%
- Max
- 100.30%
- ABBV
- 32.16%
- Q3
- 4.40%
- Median
- 0.00%
- Q1
- -131.52%
- Min
- -333.43%
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
22.90%
- Max
- 100.30%
- BIIB
- 22.90%
- Q3
- 4.40%
- Median
- 0.00%
- Q1
- -131.52%
- Min
- -333.43%
Profitability at a Glance
| Metric | ABBV | BIIB |
|---|---|---|
| Return on Equity (TTM) | -- | 7.70% |
| Return on Assets (TTM) | 10.03% | 5.95% |
| Net Profit Margin (TTM) | 5.79% | 13.81% |
| Operating Profit Margin (TTM) | 32.16% | 22.90% |
| Gross Profit Margin (TTM) | 72.03% | 78.72% |
Growth
Revenue Growth
Revenue Growth at a Glance
| Metric | ABBV | BIIB |
|---|---|---|
| 1-Year Revenue Growth | 8.57% | 2.22% |
| 3-Year Revenue CAGR | 1.75% | -0.94% |
EPS Growth
EPS Growth at a Glance
| Metric | ABBV | BIIB |
|---|---|---|
| 1-Year EPS Growth | -1.26% | -21.38% |
| 3-Year EPS CAGR | -29.13% | -25.04% |
Financial Strength
Current Ratio (MRQ)
Biogen (BIIB) at 3.07 keeps current ratio within its industry’s typical mid-range, while AbbVie (ABBV) at 0.80 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for ABBV.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.80
- Max
- 24.81
- Q3
- 11.75
- Median
- 5.57
- Q1
- 2.69
- ABBV
- 0.80
- Min
- 0.23
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.07
- Max
- 24.81
- Q3
- 11.75
- Median
- 5.57
- BIIB
- 3.07
- Q1
- 2.69
- Min
- 0.23
Debt-to-Equity Ratio (MRQ)
Only one side’s leverage can be read here: Biogen (BIIB) carries debt-to-equity ratio of 0.35 against its industry range, while AbbVie (ABBV) reports no figure this period.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 1.60
- Q3
- 0.68
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
- ABBV
- --
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.35
- Max
- 1.60
- Q3
- 0.68
- BIIB
- 0.35
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength at a Glance
| Metric | ABBV | BIIB |
|---|---|---|
| Current Ratio (MRQ) | 0.80 | 3.07 |
| Debt-to-Equity Ratio (MRQ) | -- | 0.35 |
| Net Debt / EBITDA | 2.12 | 0.64 |
Dividends
Dividend Yield (TTM)
Biogen (BIIB) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile AbbVie (ABBV) reports a yield of 3.04%, ranking against industry peers normally.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.04%
- ABBV
- 3.04%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BIIB
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
AbbVie (ABBV) reports payout ratio above 100% at 325.98%, meaning dividends exceeded current-period earnings; Biogen (BIIB) pays no dividend (payout 0.00%).
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
325.98%
- ABBV
- 325.98%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BIIB
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BIIB
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividends at a Glance
| Metric | ABBV | BIIB |
|---|---|---|
| Dividend Yield (TTM) | 3.04% | 0.00% |
| Dividend Payout Ratio (TTM) | 325.98% | 0.00% |